Mylan Scores PTAB Review Of Teva’s Copaxone Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva's three-times-a-week Copaxone has been key to its franchise protection; now that defense could quickly come under generic threat as well.
You may also be interested in...
PTAB Knocks Out Two Copaxone 40 mg Patents
Patent Trial and Appeal Board finds claims in '250 and '413 patents covering 40 mg dosage are unpatentable, giving generic manufacturers a chance at early entry once FDA approves ANDAs.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.